正子斷層掃描造影是一種核子醫學檢驗技術，目前正子斷層掃描造影可用於觀察細胞代謝、蛋白質的合成和神經傳遞功能，診斷腫瘤、心血管、神經與精神性疾病，並給予正確的治療方法。另外，為使正子斷層掃描造影成像更為精準，必須根據檢測部位給予相對的造影藥物，因此造影的藥物在開發及研究是此造影技術相當重要的環節。
目前的腫瘤診斷幾乎都是先用正子斷層掃描造影來做初步的診斷。利用腫瘤細胞會大量吸收葡萄糖的特性，以氟-18標記的去氧葡萄糖來當做造影藥物，但由於正常細胞也會吸收葡萄糖，便會產生偽陰性或偽陽性的成像結果，造成判斷上的困難。血管生成是另一項腫瘤生長和轉移不可或缺的生物過程，藉此可以利用放射性藥物標記來更準確的診斷腫瘤的生長情形。
整合素αvβ3受體存在於新生血管内皮细胞和多種腫瘤细胞表面，在血管生成中扮演著關鍵的角色，而精氨酸-甘氨酸-天冬氨酸（Arg-Gly-Asp，RGD）肽可以與整合素αvβ3結合，並具有專一性。因此，我們設計與合成非放射性藥物的4-nitrophenyl-2-fluoropropionate ( NFP )化合物來做為合成氟-18的4-nitrophenyl-
2-[18F]fluoropropionate化合物的測試，作為合成放射性RGD的前驅物。
本論文中，第一部份利用亞硫醯氯來製備氯化醯氯，在與醇反應而得到目標產物。第二部分則是利用1-(3-Dimethylaminopropyl)-3-ethyl-carbodiimide ( EDC )和N,N'-Dicyclohexylcarbodiimide ( DCC )進行酯化反應，而得到目標產物。

The Positron Emission Tomography (PET) is a nuclear medical inspection technology. Recently, it was further applied to observe the cell metabolism, protein  synthesis and psychiatric diseases and to find out proper treatments for some diseases. 
Making PET more accurate for detecting tumor growth scenario diagnosis, it is widely used PET for tumor imaging technology which is based on normal cells can absorb. glucose and them accumulate to certain level that PET really detects. Thus, PET way play a key role in drugs research and development.
	The integrin avb3 receptor relies on the surface of tumor angiogenesis endothelial cells and the tumor cells. It has been confirmed that the integrin avb3 receptor plays an important role of angiogenesis. Therefore, we design and synthesis non-radiopharmaceutical 4-nitrophenyl-2-bromopropionate (NBP) compound as precursor of radiolabelled 4-nitrophenyl-2-[18F]Fluoropropionate (18F-NFP) compound. 
Both NBP and NFP could be easily synthesized by amidation reaction of
α-halopropionate  with p-nitrophenol by using 1-(3-Dimethylaminopropyl)-
3-ethyl-carbodiimide ( EDC ) as coupling reagent

目錄	
中文摘要	I
英文摘要	II
目錄	
第一章 緒論	1
1-1 核子影像醫學	1
1-1.1核子醫學影像成像原理	2
1-1.2核子醫學影像訊號	3
1-1.3核子醫學影像掃描系統	3
1-1.4核子醫學影像偵測器及其原理	4
1-1.5單光子電腦斷層掃描攝影	4
1-1.6	正子調腦斷層攝影	5
1-2正子斷層造影簡介	8
  1-2.1正子斷層造影的原理	12
  1-2.2正子斷層造影的造影藥物	13
  1-2.3正子斷層造影的臨床應用	15
1-3應用在正子造影上的放射藥物	20
  1-3.1醣類造影劑	        20
  1-3.2胺基酸的造影劑	22
  1-3.3受體類造影劑	23
  1-3.4缺氧組織造影劑	24
  1-3.5澱粉樣蛋白 (β-Amyloid) 造影劑	25
1-4 腫瘤	29
第二章 結果與討論	35
第三章 實驗與儀器	42
3-1 實驗方法	42
3-2 溶劑之乾燥	47
3-3 實驗儀器與測試方法	48
第四章 結論	50
第五章 光譜	51
第六章 參考資料	56

[1] nuclear medicine; http://memo.cgu.edu.tw/Secretariat/news/49/research/research_1.htm
[2] Single Photon Emission Computed Tomography; https://en.wikipedia.org/wiki/Single-photon_emission_computed_tomography
[3] Modes of radioactive decay. Cherry SR. Sorenson JA, Phelps ME. ed. Physics in Nuclear Medicine. 3rd ed. Chapter 4, Saunders, Philadelphia, PA. 2003, 19-30
[4] Benedict Cassen; https://de.wikipedia.org/wiki/Benedict_Cassen
[5] Frederick, J.B. J Nucl Med. 1976, 17, 518.
[6] Hans, A.k. Biographical Memoirs of fellows of the Royal Societ, 1972, 18: 628.
[7] Michel Matthew Ter-Pogossian; https://en.wikipedia.org/wiki/Michel_Ter-Pogossian
[8] Positron emission tomography. Cherry SR. Sorenson JA, Phelps ME. ed. Physics in Nuclear Medicine. 3rd ed. Chapter 18, 2003, 325-359.
[9] Radiation detection. Cherry SR. Sorenson JA, Phelps ME. ed. Physics in Nuclear Medicine. 3rd ed. Chapter 7, 2003, 89-108.
[10] Wahl, R. L., Eds. Principles and Practice of Positron Emission Tomography, 2003.
[11] Tamaki, N.; Kuge, Y., Eds. PET and molecular imaging: state of the art and future perspectives, 2004
[12] Meikle, S.R.; Bailey, D.L.;Hooper, P.K. J Nucl Med. 1995, 36, 1680.
[13]雙和醫院正子電腦斷層（PET-CT）簡介
[14]Fowler, J. S.; Wolf, A. P. Acc. Chem. Res. 1997, 30, 181. 
[15] Elsinga, P. H. Methods, 2002, 27, 208. 
[16]. Schlyer, D. J. Annals Academy Med. 2004, 33, 146−154.
[17] Smart, B. E. J. Fluorine Chem. 2001, 109, 3.
[18 ] Ding, Y.-S. J. Fluorine Chem. 2000, 101, 291−295. 
[19] Varagnolo, L.; Stokkel, M. P. M.; Mazzi, U.; Pauwels, E. K. J. Nucl. Med. Biol. 2000, 27, 103. 
[20] Beuthien-Baumann, B.; Hamacher, K.; Oberdorfer, F.; Steinbach, J. Carbohydr. Res. 2000, 327, 107.
[21] Katzenellenbogen, J. A. J. Fluorine Chem. 2001, 109, 49. 
[22] Couturier, O.; Luxen, A.; Chatal, J.-F.; Vuillez, J. P.; Rigo, P.; Hustinx, R. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 1182.
[23]Tumor; http://wwwu.tsgh.ndmctsgh.edu.tw/petc/C01-2.htm
[24]  Chang, B.S.; Lowenstein D.H.; Epilepsy. N. Engl. J. Med. 2003, 349, 1257.
[25] Heiss, W. D.; Hilker, R. Eur. J. Neurol. 2004, 11, 5. 
[26] Eckert, T.; Eidelberg, D. NeuroRx, 2005, 2, 361.
[27] Alavi, A.; Reivich, M. Semin. Nucl. Med. 2002, 32, 2.
[28] Cook,G.J.R.; Fogelman,I.; Maisey, M.N. Semin Nucl Med. 1996, 26, 308.
[29] Strauss, L.G. Eur. J Nucl Med. 1996, 23, 1409.
[30] Couturier, O.; Luxen, A.; Chatal, J. F.; Vuillez, J. P.; Rigo, P.; Hustinx, R. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 1182.
[31] Laverman, P.; Boerman, O. C.; Corstens, F. H. M.; Oyen, W. J. G. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 681.
[32] Wester, H. J.; Herz, M.; Weber, W.; Heiss, P.; Senekowitsch-Schmidtke, R.; Schwaiger, M.; Stöcklin, G. J. Nucl. Med. 1999, 40, 205.
[33] Weber, W. A.; Wester, H. J.; Grosu, A. L.; Herz, M.; Dzewas, B; Feldmann, H.J.; Molls, M.; Stöcklin, G.; Schwaiger, M. Eur. J. Nucl. Med. Mol. Imaging, 2000, 27, 542. 
[34] Pöpperl, G.; Götz, C.; Rachinger, W.; Gildehaus, F.J.; Tonn, J. C.; Tatsch, K. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 1464. 
[35] Wang, H.E.; Wu, S.Y.; Chang, C.W.; Liu, R.S.; Hwang, L. C.; Lee, T.W.; Chen, J.C.; Hwang, J.J. Nucl. Med. Biol. 2005, 32, 367.
[36] Inoue, T.; Shibasaki, T.; Oriuchi, N.; Aoyagi, K.; Tomiyoshi, K.; Amano, S.; Mikuni, M.; Ida, I.; Aoki, J.; Endo, K. J. Nucl. Med. 1999, 40, 399. 
[37]Inoue, T.; Koyama, K.; Oriuchi, N.; Alyafei, S.; Yuan, Z.; Suzuki, H.; Takeuchi, K.; Tomaru, Y.; Tomiyoshi, K.; Aoki, J.; Endo, K. Radiology, 2001, 220, 554. 
[38]Watanabe, H.; Inoue, T.; Shinozaki, T.; Yanagawa, T.; Ahmed, A. R.; Tomiyoshi, K.; Oriuchi, N.; Tokunaga, M.; Aoki, J.; Endo, K. Takagishi, K. Eur. J. Nucl. Med. Mol. Imaging, 2000, 27, 1509.
[39] Börner, A. R.; Langen, K.-J.; Herzog, H.; Hamacher, K.; Müller-Mattheis, V.; Schmitz, T.; Ackermann, R.; Coenen, H. H. Nucl. Med. Biol. 2001, 28, 287. 
[40] Langen, K.-J.; Jarosch, M.; Hamacher, K.; Mühlensiepen, H.; Weber, F.; Floeth, F.; Pauleit, D.; Herzog, H.; Coenen, H. H. Nucl. Med. Biol., 2004, 31, 67. 
[41] Langen, K.-J.; Hamacher, K.; Bauer, D.; Börner, S.; Pauleit, D.; Herzog, H.; Floeth, F. W.; Zilles, K.; Coenen, H. H. J. Cereb. Blood Flow Metab., 2005, 25, 607.
[42] Mintun, M. A.; Welch, M. J.; Siegel, B. A.; Mathias, C. J.; Brodack, J. W.; McGuire, A. H.; Katzenellenbogen, J. A. Radiology, 1988, 169, 45.
[43] Höckel, M.; Schlenger, K.; Mitze, M.; Schäffer, U.; Vaupel, P. Semin. Radiat. Oncol., 1996, 6, 3. 
[44] Brizel, D. M.; Sibley, G. S.; Prosnitz, L. R.; Scher, R. L.; Dewhrist, M. W. Int. J. Radiation Oncology Biol. Phys., 1997, 38, 285.
[45] Brizel, D. M.; Scully, S. P.; Harrelson, J. M.; Layfield, L. J.; Bean, J. M.; Prosnitz, L. R.; Dewhirst, M. W. Cancer Res., 1996, 56, 941.
[46] Jerabek, P. A.; Patrick, T. B.; Kilbourn, M. R.; Dischino, D. D.; Welch, M. J. Appl. Radiat. Isot., 1986, 37, 599.
[47] Wang, C.; Yan, Q.; Liu, H. B.; Zhou X. H.; Xiao, S. J. Langmuir., 2011, 27, 12058. 
[48] Angiogenesis; http://highscope.ch.ntu.edu.tw/wordpress/?p=942
[49] Integrin; http://www.wikiwand.com/zh-mo/%E6%95%B4%E5%90%88%E7%B4%A0